# QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

> **NCT06751277** · PHASE2 · NOT_YET_RECRUITING · sponsor: **xiang yang** · enrollment: 26 (estimated)

## Conditions studied

- Recurrent or Metastatic Endometrial Cancer

## Interventions

- **DRUG:** QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706

## Key facts

- **NCT ID:** NCT06751277
- **Lead sponsor:** xiang yang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751277, "QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06751277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*